Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AMBQ research report →
Range $70 – $125
Price Chart
About the company
Ambiq Micro, Inc. specializes in designing highly energy-efficient integrated circuits, tailored specifically for applications where power consumption is a critical factor. The company leverages its advanced subthreshold power-optimized technology to produce ultra-low-power real-time clocks and microcontrollers.
- CEO
- Fumihide Esaka
- IPO
- 2025
- Employees
- 201
- HQ
- Austin, TX, US
Get TickerSpark's AI analysis on AMBQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $1.23B
- P/E
- -29.17
- Fwd P/E
- 931.68
- PEG
- -0.87
- P/S
- 10.41
- P/B
- 2.95
- EV/EBITDA
- -29.10
- Div Yield
- 0.00%
- Gross Margin
- 44.84%
- Op Margin
- -35.97%
- Net Margin
- -29.72%
- ROE
- -11.60%
- ROIC
- -10.32%
Latest fiscal year · YoY change
- Revenue
- $72.51M-4.7%
- Gross Profit
- $25.70M+5.8%
- Op Income
- $-41,143,000
- Net Income
- $-36,461,000+8.1%
- EPS
- $-4.57-46.0%
- OCF Growth
- +8.1%
- FCF Growth
- -7.8%
- Beta
- 5.64
- RSI (14)
- 39
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Ambiq posted a strong third quarter with net sales up 110% year over year, gross margin expanding, and management signaling continued growth into 2027 despite some supply constraints.· November 10, 2026
- Q3 net sales were $38.1 million, up 110% year over year, marking the sixth consecutive quarter of sequential growth.
- Non-GAAP gross profit rose 128% year over year to $18.6 million, and non-GAAP gross margin improved to 48.7%, up 390 basis points.
- Management said demand remained broad-based across customers, products, and form factors, with 7 customers above $1 million in quarterly sales versus 3 a year ago.
- Full-year 2026 net sales are expected to be approximately $140 million, nearly doubling from 2025.
- Fourth-quarter net sales are guided to $43.5 million to $44.5 million, with some demand still left unfilled because of short lead times.
Ambiq reported third-quarter net sales of $38.1 million, up 110% year over year. Non-GAAP gross profit was $18.6 million, up 128% year over year, and non-GAAP gross margin was 48.7%, up 390 basis points year over year. Non-GAAP R&D was $13.1 million, up 90.1% year over year, and non-GAAP SG&A was $9.6 million, up 53.8% year over year. Non-GAAP net loss was $1.2 million, or $0.05 per share, improving by $2.8 million year over year. Cash and cash equivalents were $363.5 million with no debt. For Q4, the company expects net sales of $43.5 million to $44.5 million, non-GAAP gross margin roughly flat with Q3, non-GAAP operating expense of $25.5 million to $26.5 million, and non-GAAP loss per share of $0.09 to $0.03. Full-year 2026 net sales are expected to be approximately $140 million, compared with an initial expectation of more than $100 million, and gross margin is expected to expand by almost 300 basis points year over year.
Fumihide Esaka described the quarter as evidence of accelerating demand driven by edge AI adoption, stronger customer launches, and new customer additions. He said the business is still early in a multiyear shift toward intelligence at the edge and emphasized that Ambiq’s ultra-low-power SPOT platform is well positioned for that transition. He highlighted commercial traction in wearables and expansion into non-wearables such as infrastructure monitoring and digital health, while also pointing to new AI software offerings and customer-developed model deployment as important validation of the strategy.
Jeff Winzeler said top-line growth translated into more than doubled gross profit, helped by stronger mix, manufacturing efficiencies, and greater value capture from SPOT. He cited non-GAAP gross margin of 48.7%, cash of $363.5 million, and no debt, while noting that R&D and SG&A rose as the company funded multiple product programs and scaled as a public company. On the outlook, he guided Q4 revenue to $43.5 million to $44.5 million, gross margin roughly flat, and operating expense of $25.5 million to $26.5 million, including $0.5 million of IP spending and tape-out-related costs for Atomiq110 and Apollo340.
Analysts focused heavily on whether supply was still limiting sales and how much demand might roll into 2027. Management said some demand still could not be filled because of short lead times, but supply-chain partners helped them meet most customer needs, and expedites helped in a few cases. Questions also addressed OpEx timing and 2027 spending, with Jeff saying some costs slipped into Q3/Q4 and that it was too early to guide 2027 run-rate spending. On diversification, Scott Hanson highlighted infrastructure monitoring and digital health use cases, and said the first Ambiq-developed AI model shipped this quarter was a meaningful proof point, though still immaterial to revenue.
The bull case is that demand appears to be broadening and accelerating, with management expecting growth to continue into 2027 and citing strong customer forecasts, new design wins, and expanding product adoption. The company is also seeing higher ASPs as customers move to Apollo5, while software and AI-model offerings could add a new layer of differentiation over time.
The main risk discussed on the call is supply constraints: management said some demand remains unfilled because customer upside arrives with short lead times, and they cannot always count on expedites. OpEx is also rising as the company funds new tape-outs and IP work, and management declined to quantify 2027 spending or the eventual revenue mix from non-wearables and AI software, which leaves some execution uncertainty.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 83.1%
- Shares Outstanding
- 24.88M
- Float Shares
- 20.68M
of shares held by institutions
191 13F filers
Buy/sell ratio 0.14. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 1.76M | ▲ 381.21K |
| State Street Corp | 1.14M | ▲ 276.38K |
| T. Rowe Price Investment Management, Inc. | 1.01M | ▼ 261.19K |
| D. E. Shaw & Co., Inc. | 983.92K | ▲ 983.92K |
| Vanguard Capital Management LLC | 912.78K | ▲ 144.25K |
| Atreides Management, LP | 877.12K | ▲ 14.95K |
| Two Sigma Investments, LP | 651.79K | ▲ 614.99K |
| Alliancebernstein L.P. | 609.61K | ▼ 76.49K |
| Geode Capital Management, LLC | 515.76K | ▲ 176.43K |
| Goldman Sachs Group Inc | 446.95K | ▲ 33.52K |
| Artisan Partners Limited Partnership | 331.44K | ▲ 331.44K |
| Vanguard Group Inc | 328.18K | ▲ 20.35K |
Held by 197 ETFs
Biggest fund positions in AMBQ by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Hanson Scott McLean | other | 7,000 |
| Nov 16, 26 | Hanson Scott McLean | sell | 4,084 |
| Nov 16, 26 | Hanson Scott McLean | sell | 2,900 |
| Nov 16, 26 | Hanson Scott McLean | sell | 16 |
| Nov 16, 26 | Hanson Scott McLean | other | 7,000 |
| Nov 13, 26 | Esaka Fumihide | other | 54,821 |
| Nov 12, 26 | Esaka Fumihide | other | 50,000 |
| Nov 13, 26 | Esaka Fumihide | sell | 5,600 |
| Nov 13, 26 | Esaka Fumihide | sell | 9,325 |
| Nov 12, 26 | Esaka Fumihide | sell | 17,400 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AMBQ coverage
Recent articles, reports, and earnings notes.
Want a deeper read on AMBQ?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
